Effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes

Effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes - VictOza and Gastric [U] Emptying

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010341

Enrollment

Registered

2013-03-28

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T2DM

Interventions

Liraglutide therapy is initiated at 0.3 mg daily, and the dose is increased by 0.3 mg every 3 days to 0.9 mg.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: T2DM

Exclusion criteria

Exclusion criteria: T1DM Patients who are judged by investigators to be inappropriate for inclusion in this study.

Design outcomes

Primary

Measure	Time frame
The half gastric emptying time (T1/2) and the lag phase (Tlag) before and after liraglutide treatment	—

Countries

Japan

Contacts

Public ContactYoshio Nagai

St. Marianna University School of Medicine Division of Metabolism and Endocrinology, Department of Internal Medicine

ynagai@marianna-u.ac.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026